Ritonavir

• Anti-HIV Agents
• HIV Protease Inhibitors
• ATC:J05AE03

• Abbott 84538
• Kaletra
• Norvir
• Norvir Sec
• Ritonavir [Usan]

• Kaletra (Lopinavir + Ritonavir)

C₃₇H₄₈N₆O₅S₂

http://www.rxlist.com/cgi/generic2/ritonavirsol.htm

Ritonavir FDA

Ritonavir MSDS

No information avaliable

720.946 g/mol

No information avaliable

Practically insoluble

Solid

4.941

Capsule (100 mg); Solution (80 mg/mL of ritonavir)

Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.

Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Ritonavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

The absolute bioavailability of ritonavir has not been determined.

Human experience of acute overdose with NORVIR is limited. One patient in clinical trials took NORVIR 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.

No information avaliable

Human immunodeficiency virus